Biogen Idec's CEO Calls It Quits

It has to be a little disheartening for a CEO to announce his retirement and see shares of the company's stock open up 2%, but such is the life of Biogen Idec's (Nasdaq: BIIB  ) James Mullen.

In addition to small-fry investors, I imagine Carl Icahn is smiling a little, too. You'll recall that Icahn launched two attempts to board the M.S. Biogen, with the second ending in a pair of board seats for his slate of nominees.

Investors are justified to be upset with Mullen's performance of late, especially compared with some of the company's drug-making brethren.

Company

Market Cap (in Billions)

Share Increase
Over Past 3 Years

Biogen Idec

$15.5

13.4%

Gilead Sciences (Nasdaq: GILD  )

$39.0

64.7%

Celgene (Nasdaq: CELG  )

$25.6

72.0%

Bristol-Myers Squibb (NYSE: BMY  )

$49.9

(4.37%)

Source: Google Finance.

But Mullen's nearly decade-long tenure as CEO hasn't been all bad. He oversaw the merger with Idec Pharmaceuticals, which brought in Rituxan and the approval and reapproval of Tysabri, which it markets with Elan (NYSE: ELN  ) . Most recently, the company managed to remove part of a deal between Elan and Johnson & Johnson (NYSE: JNJ  ) that might have reduced Biogen's value as a takeover target.

To get Biogen's shares out of their funk, Mullen's successor will need to increase revenue of both its current offerings as well as new ones. There's potential for Tysabri sales to accelerate again if Elan and Biogen can get the progressive multifocal leukoencephalopathy (PML) side effect to a reasonable level. It also has quite a few drugs in the pipeline, including Acorda Therapeutics' (Nasdaq: ACOR  ) Fampridine-SR, to which Biogen licensed the rights excluding the U.S.

And of course, there's still the possibility of orchestrating a sale of the company, although the issues from the first attempted sale still remain. Keep your head up, Mullen; I'm not sure your successor will be able to do much better.

Is Mullen's departure a good thing for the company or a minor milestone in the company's timeline? Let us know in the comments box below.

Elan is a Motley Fool Rule Breakers selection. The newsletter analysts are always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a Motley Fool Income Investor pick. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1077318, ~/Articles/ArticleHandler.aspx, 7/29/2014 11:04:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement